$AGEN Income Statement | Understand Stock

$AGEN

$6.16 -$0.17 (2.69%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Research and Development
Pre-Commercial Product Revenue
Service Revenue
Royalty sales milestone
Other Revenue
Non-Cash Royalty Revenue Related to the Sale of Future Royalties and Milestones
Non-Cash Royalty Revenue Related to the Sale of Future Royalties
Non-Cash Revenue Related to the Sale of Future Royalties
Total revenues

Operating expenses:
Cost of revenue
Research and development
General and administrative
Fair value adjustments
Operating loss
Other income (expense):
Gain on extinguishment of debt
Loss on modification of debt
Non-operating income (expense)
MiNK Therapeutics, Inc. equity method investment fair value adjustment
Gain from deconsolidation of MiNK Therapeutics, Inc.
Interest expense, net
Net loss

Dividends on Series A-1 convertible preferred stock
Less: net loss attributable to non-controlling interest
Net loss attributable to Agenus Inc. common stockholders
Basic and diluted net loss attributable to Agenus Inc. common stockholders
Basic and diluted
Per common share data:
Basic net loss attributable to Agenus Inc. common stockholders
Diluted net loss attributable to Agenus Inc. common stockholders
Weighted average number of Agenus Inc. common shares outstanding:
Basic
Diluted
Other comprehensive income (loss):
Foreign currency translation gain (loss)
Other comprehensive income (loss)
Comprehensive income (loss)

Comments